BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

607 related articles for article (PubMed ID: 23857969)

  • 21. Prediction of surgical outcome using plasma Epstein-Barr virus dna and (18)F-FDG PET-CT scan in recurrent nasopharyngeal carcinoma.
    Chan JY; Chow VL; Mok VW; Ho AC; Wei WI
    Head Neck; 2012 Apr; 34(4):541-5. PubMed ID: 21523844
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic significance of 18F-FDG PET parameters and plasma Epstein-Barr virus DNA load in patients with nasopharyngeal carcinoma.
    Chang KP; Tsang NM; Liao CT; Hsu CL; Chung MJ; Lo CW; Chan SC; Ng SH; Wang HM; Yen TC
    J Nucl Med; 2012 Jan; 53(1):21-8. PubMed ID: 22213820
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Low value of whole-body dual-modality [18f]fluorodeoxyglucose positron emission tomography/computed tomography in primary staging of stage I-II nasopharyngeal carcinoma: a nest case-control study.
    Xiao BB; Chen QY; Sun XS; Li JB; Luo DH; Sun R; Lin DF; Zhang X; Fan W; Lv XF; Han LJ; Wen YF; Yuan L; Guo SS; Liu LT; Liu SL; Tang QN; Liang YJ; Li XY; Lin C; Guo L; Mai HQ; Tang LQ
    Eur Radiol; 2021 Jul; 31(7):5222-5233. PubMed ID: 33416977
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Significance of cell-free Epstein-Barr virus DNA in monitoring prognosis of nasopharyngeal carcinoma].
    Cao SM; Min HQ; Gao JS; Hong MH; Xiao XB; Zhang CQ; Liu XD; Zhang AL; Guo X
    Ai Zheng; 2003 Mar; 22(3):302-6. PubMed ID: 12654192
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Maximal standard uptake values of
    Sun XS; Liang YJ; Liu SL; Chen QY; Guo SS; Wen YF; Liu LT; Xie HJ; Tang QN; Li XY; Yan JJ; Tang LQ; Mai HQ
    BMC Cancer; 2019 Sep; 19(1):908. PubMed ID: 31511059
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Plasma Epstein-Barr viral DNA complements TNM classification of nasopharyngeal carcinoma in the era of intensity-modulated radiotherapy.
    Zhang L; Tang LQ; Chen QY; Liu H; Guo SS; Liu LT; Guo L; Mo HY; Zhao C; Guo X; Cao KJ; Qian CN; Zeng MS; Shao JY; Sun Y; Ma J; Hong MH; Mai HQ
    Oncotarget; 2016 Feb; 7(5):6221-30. PubMed ID: 26716900
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nasopharyngeal carcinoma staging by (18)F-fluorodeoxyglucose positron emission tomography.
    Chang JT; Chan SC; Yen TC; Liao CT; Lin CY; Lin KJ; Chen IH; Wang HM; Chang YC; Chen TM; Kang CJ; Ng SH
    Int J Radiat Oncol Biol Phys; 2005 Jun; 62(2):501-7. PubMed ID: 15890593
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Relationship between pretreatment level of plasma Epstein-Barr virus DNA, tumor burden, and metabolic activity in advanced nasopharyngeal carcinoma.
    Ma BB; King A; Lo YM; Yau YY; Zee B; Hui EP; Leung SF; Mo F; Kam MK; Ahuja A; Kwan WH; Chan AT
    Int J Radiat Oncol Biol Phys; 2006 Nov; 66(3):714-20. PubMed ID: 17011447
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Negative plasma Epstein-Barr virus DNA nasopharyngeal carcinoma in an endemic region and its influence on liquid biopsy screening programmes.
    Nicholls JM; Lee VH; Chan SK; Tsang KC; Choi CW; Kwong DL; Lam KO; Chan SY; Tong CC; So TH; Leung TW; Luk MY; Khong PL; Lee AW
    Br J Cancer; 2019 Oct; 121(8):690-698. PubMed ID: 31527689
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Utilization of the lymph node-to-primary tumor ratio of PET standardized uptake value and circulating Epstein-Barr virus DNA to predict distant metastasis in nasopharyngeal carcinoma.
    Shen EY; Hung TM; Tsan DL; Cheng NM; Kang CJ; Huang SF; Hsu CL; Lin CY; Wang HM; Hsieh JC; Cheng AJ; Fan KH; Chang JT
    Radiother Oncol; 2022 Dec; 177():1-8. PubMed ID: 35568282
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of plasma Epstein-Barr virus DNA load to distinguish nasopharyngeal carcinoma patients from healthy high-risk populations in Southern China.
    Ji MF; Huang QH; Yu X; Liu Z; Li X; Zhang LF; Wang P; Xie SH; Rao HL; Fang F; Guo X; Liu Q; Hong MH; Ye W; Zeng YX; Cao SM
    Cancer; 2014 May; 120(9):1353-60. PubMed ID: 24477877
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prospective study of prognostic value of Raf kinase inhibitory protein and pretreatment plasma Epstein-Barr virus DNA for distant metastasis in locoregionally advanced nasopharyngeal carcinoma.
    Li SW; Wang H; Xiang YQ; Zhang HB; Lv X; Xia WX; Zeng MS; Mai HQ; Hong MH; Guo X
    Head Neck; 2013 Apr; 35(4):579-91. PubMed ID: 22605662
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of Epstein-Barr virus DNA level in plasma, peripheral blood cell and tumor tissue in nasopharyngeal carcinoma.
    Shao JY; Zhang Y; Li YH; Gao HY; Feng HX; Wu QL; Cui NJ; Cheng G; Hu B; Hu LF; Ernberg I; Zeng YX
    Anticancer Res; 2004; 24(6):4059-66. PubMed ID: 15736452
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Efficiency comparison between PET/CT and conventional work-up for evaluating distant metastasis of nasopharyngeal carcinoma].
    Lin S; Li X; Wu H; Lu J; Liang B; Peng X; Li S; Yu L; Liu X
    Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2012 Jun; 26(12):529-32. PubMed ID: 22934422
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The diagnostic and prognostic values of plasma Epstein-Barr virus DNA for residual cervical lymphadenopathy in nasopharyngeal carcinoma patients: a retrospective study.
    Liu SL; Sun XS; Li XY; Tang LQ; Chen QY; Lin HX; Liang YJ; Yan JJ; Lin C; Guo SS; Liu LT; Li Y; Xie HJ; Tang QN; Liang H; Guo L; Mai HQ
    Cancer Commun (Lond); 2019 Mar; 39(1):14. PubMed ID: 30925939
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 18F-FDG PET can replace conventional work-up in primary M staging of nonkeratinizing nasopharyngeal carcinoma.
    Liu FY; Lin CY; Chang JT; Ng SH; Chin SC; Wang HM; Liao CT; Chan SC; Yen TC
    J Nucl Med; 2007 Oct; 48(10):1614-9. PubMed ID: 17873135
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pretreatment
    Lin HC; Chan SC; Cheng NM; Liao CT; Hsu CL; Wang HM; Lin CY; Chang JT; Ng SH; Yang LY; Yen TC
    Oral Oncol; 2020 May; 104():104628. PubMed ID: 32163890
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Individualized concurrent chemotherapy by pretreatment plasma Epstein-Barr viral DNA in II-III stage nasopharyngeal carcinoma: A propensity score matching analysis using a large cohort.
    Sun XS; Chen WH; Liu SL; Liang YJ; Chen QY; Guo SS; Wen YF; Liu LT; Xie HJ; Tang QN; Li XY; Yan JJ; Mai HQ; Tang LQ
    Cancer Med; 2019 Aug; 8(9):4214-4225. PubMed ID: 31210417
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Correlation of Epstein-Barr virus DNA in cell-free plasma, functional imaging and clinical course in locally advanced nasopharyngeal cancer: a pilot study.
    Mäkitie AA; Reis PP; Irish J; Zhang T; Chin SF; Chen X; Marriott C; Keller A; Perez-Ordonez B; Kamel-Reid S; Siu LL
    Head Neck; 2004 Sep; 26(9):815-22. PubMed ID: 15350028
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The role of plasma Epstein-Barr virus DNA in the management of recurrent nasopharyngeal carcinoma.
    Chan JY; Wong ST
    Laryngoscope; 2014 Jan; 124(1):126-30. PubMed ID: 23686740
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.